← Back to headlines
Abivax Stock Plunges Amid Cancer Concerns in Ulcerative Colitis Trial
Abivax stock plunged significantly after cancer cases emerged in its ulcerative colitis trial, overshadowing otherwise positive efficacy data. The concerns have led to a record drop for the company's shares.
2 Jun, 08:23 — 2 Jun, 15:14
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (46/100)3 sources25/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
Yahoo
Center
Right1
Right (1)
seeking-alpha
Far R1
Far Right (1)
zerohedge
Geographic diversity— 1 region4/34
US3
ℹAll sources from US region
Sources
Showing 3 of 3 sources
YahooMostly Factual68d ago
Abivax Grounded as Cancer Cases Cast a Shadow Over Best-in-Class Trial Data
Read full article →seeking-alphaMixed68d ago
Abivax plunges 32% as ulcerative colitis drug efficacy overshadowed by cancer concerns
Read full article →zerohedgeLow68d ago
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval. Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obef...
By Tyler Durden
Read full article →Coverage Timeline
First report: seeking-alpha · 2 Jun, 08:23|Full coverage: 3 · 7h|Window: 7h
Left-leaningCenterRight-leaning
